Regulation of prostaglandin transporters in colorectal neoplasia

Vijaykumar R. Holla, Michael G. Backlund, Peying Yang, Robert A. Newman, Raymond N. DuBois

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Prostaglandin E2 (PGE2) promotes cancer progression by affecting cell proliferation, apoptosis, angiogenesis, and the immune response. It has been reported that PGE2 is transported or passes through the cell membrane via prostaglandin-specific transporters including the prostaglandin transporter (PGT, an influx transporter) and the multidrug resistance-associated protein 4 (an efflux transporter). PGT can facilitate the removal of PGE2 from the extracellular milieu by transporting it into the cell, where 15-hydroxyprostaglandin dehydrogenase (15-PGDH) then oxidizes PGE2 into 15-keto PGE2. We previously reported that 15-PGDH expression is reduced in most colorectal cancers, indicating the tumor suppressor role of this gene. In the present study, we show that PGT expression is also decreased (whereas multidrug resistance-associated protein 4 expression is elevated) in human colorectal cancer specimens (compared with expression in normal mucosa) and in colorectal cancer cell lines. Furthermore, we found that PGT expression decreased in premalignant adenomas in Apcmin mice and was partially restored (in human colorectal cancer cell lines) by treatment with a DNAd emethylating agent or histone deacetylase inhibitor. Forced PGT overexpression in vitro reduced extracellular PGE2 levels and increased intracellular levels of its catabolic product 15-keto PGE2. Our data suggest that the existing model to explain increased PGE2 in colorectal neoplasia should be modified to include the novel mechanism of coordinated up- and down-regulation of genes involved in PGE2 transport.

Original languageEnglish (US)
Pages (from-to)93-99
Number of pages7
JournalCancer Prevention Research
Volume1
Issue number2
DOIs
StatePublished - Jul 2008
Externally publishedYes

Fingerprint

Dinoprostone
Prostaglandins
15-hydroxyprostaglandin dehydrogenase
Colorectal Neoplasms
Neoplasms
Multidrug Resistance-Associated Proteins
Cell Line
Histone Deacetylase Inhibitors
Tumor Suppressor Genes
Adenoma
Mucous Membrane
Up-Regulation
Down-Regulation
Cell Proliferation
Cell Membrane
Apoptosis
Genes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Holla, V. R., Backlund, M. G., Yang, P., Newman, R. A., & DuBois, R. N. (2008). Regulation of prostaglandin transporters in colorectal neoplasia. Cancer Prevention Research, 1(2), 93-99. https://doi.org/10.1158/1940-6207.CAPR-07-0009

Regulation of prostaglandin transporters in colorectal neoplasia. / Holla, Vijaykumar R.; Backlund, Michael G.; Yang, Peying; Newman, Robert A.; DuBois, Raymond N.

In: Cancer Prevention Research, Vol. 1, No. 2, 07.2008, p. 93-99.

Research output: Contribution to journalArticle

Holla, VR, Backlund, MG, Yang, P, Newman, RA & DuBois, RN 2008, 'Regulation of prostaglandin transporters in colorectal neoplasia', Cancer Prevention Research, vol. 1, no. 2, pp. 93-99. https://doi.org/10.1158/1940-6207.CAPR-07-0009
Holla, Vijaykumar R. ; Backlund, Michael G. ; Yang, Peying ; Newman, Robert A. ; DuBois, Raymond N. / Regulation of prostaglandin transporters in colorectal neoplasia. In: Cancer Prevention Research. 2008 ; Vol. 1, No. 2. pp. 93-99.
@article{5da51090a5d5445886a5e45aebaa5129,
title = "Regulation of prostaglandin transporters in colorectal neoplasia",
abstract = "Prostaglandin E2 (PGE2) promotes cancer progression by affecting cell proliferation, apoptosis, angiogenesis, and the immune response. It has been reported that PGE2 is transported or passes through the cell membrane via prostaglandin-specific transporters including the prostaglandin transporter (PGT, an influx transporter) and the multidrug resistance-associated protein 4 (an efflux transporter). PGT can facilitate the removal of PGE2 from the extracellular milieu by transporting it into the cell, where 15-hydroxyprostaglandin dehydrogenase (15-PGDH) then oxidizes PGE2 into 15-keto PGE2. We previously reported that 15-PGDH expression is reduced in most colorectal cancers, indicating the tumor suppressor role of this gene. In the present study, we show that PGT expression is also decreased (whereas multidrug resistance-associated protein 4 expression is elevated) in human colorectal cancer specimens (compared with expression in normal mucosa) and in colorectal cancer cell lines. Furthermore, we found that PGT expression decreased in premalignant adenomas in Apcmin mice and was partially restored (in human colorectal cancer cell lines) by treatment with a DNAd emethylating agent or histone deacetylase inhibitor. Forced PGT overexpression in vitro reduced extracellular PGE2 levels and increased intracellular levels of its catabolic product 15-keto PGE2. Our data suggest that the existing model to explain increased PGE2 in colorectal neoplasia should be modified to include the novel mechanism of coordinated up- and down-regulation of genes involved in PGE2 transport.",
author = "Holla, {Vijaykumar R.} and Backlund, {Michael G.} and Peying Yang and Newman, {Robert A.} and DuBois, {Raymond N.}",
year = "2008",
month = "7",
doi = "10.1158/1940-6207.CAPR-07-0009",
language = "English (US)",
volume = "1",
pages = "93--99",
journal = "Cancer Prevention Research",
issn = "1940-6207",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Regulation of prostaglandin transporters in colorectal neoplasia

AU - Holla, Vijaykumar R.

AU - Backlund, Michael G.

AU - Yang, Peying

AU - Newman, Robert A.

AU - DuBois, Raymond N.

PY - 2008/7

Y1 - 2008/7

N2 - Prostaglandin E2 (PGE2) promotes cancer progression by affecting cell proliferation, apoptosis, angiogenesis, and the immune response. It has been reported that PGE2 is transported or passes through the cell membrane via prostaglandin-specific transporters including the prostaglandin transporter (PGT, an influx transporter) and the multidrug resistance-associated protein 4 (an efflux transporter). PGT can facilitate the removal of PGE2 from the extracellular milieu by transporting it into the cell, where 15-hydroxyprostaglandin dehydrogenase (15-PGDH) then oxidizes PGE2 into 15-keto PGE2. We previously reported that 15-PGDH expression is reduced in most colorectal cancers, indicating the tumor suppressor role of this gene. In the present study, we show that PGT expression is also decreased (whereas multidrug resistance-associated protein 4 expression is elevated) in human colorectal cancer specimens (compared with expression in normal mucosa) and in colorectal cancer cell lines. Furthermore, we found that PGT expression decreased in premalignant adenomas in Apcmin mice and was partially restored (in human colorectal cancer cell lines) by treatment with a DNAd emethylating agent or histone deacetylase inhibitor. Forced PGT overexpression in vitro reduced extracellular PGE2 levels and increased intracellular levels of its catabolic product 15-keto PGE2. Our data suggest that the existing model to explain increased PGE2 in colorectal neoplasia should be modified to include the novel mechanism of coordinated up- and down-regulation of genes involved in PGE2 transport.

AB - Prostaglandin E2 (PGE2) promotes cancer progression by affecting cell proliferation, apoptosis, angiogenesis, and the immune response. It has been reported that PGE2 is transported or passes through the cell membrane via prostaglandin-specific transporters including the prostaglandin transporter (PGT, an influx transporter) and the multidrug resistance-associated protein 4 (an efflux transporter). PGT can facilitate the removal of PGE2 from the extracellular milieu by transporting it into the cell, where 15-hydroxyprostaglandin dehydrogenase (15-PGDH) then oxidizes PGE2 into 15-keto PGE2. We previously reported that 15-PGDH expression is reduced in most colorectal cancers, indicating the tumor suppressor role of this gene. In the present study, we show that PGT expression is also decreased (whereas multidrug resistance-associated protein 4 expression is elevated) in human colorectal cancer specimens (compared with expression in normal mucosa) and in colorectal cancer cell lines. Furthermore, we found that PGT expression decreased in premalignant adenomas in Apcmin mice and was partially restored (in human colorectal cancer cell lines) by treatment with a DNAd emethylating agent or histone deacetylase inhibitor. Forced PGT overexpression in vitro reduced extracellular PGE2 levels and increased intracellular levels of its catabolic product 15-keto PGE2. Our data suggest that the existing model to explain increased PGE2 in colorectal neoplasia should be modified to include the novel mechanism of coordinated up- and down-regulation of genes involved in PGE2 transport.

UR - http://www.scopus.com/inward/record.url?scp=57249086646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57249086646&partnerID=8YFLogxK

U2 - 10.1158/1940-6207.CAPR-07-0009

DO - 10.1158/1940-6207.CAPR-07-0009

M3 - Article

VL - 1

SP - 93

EP - 99

JO - Cancer Prevention Research

JF - Cancer Prevention Research

SN - 1940-6207

IS - 2

ER -